Show simple item record

dc.contributor.authorAkyüz, Şükrü
dc.contributor.authorÇalık, Ali Nazmi
dc.contributor.authorYaylak, Barış
dc.contributor.authorOnuk, Tolga
dc.contributor.authorEren, Semih
dc.contributor.authorKolak, Zeynep
dc.contributor.authorMollaalioğlu, Feyza
dc.contributor.authorDurak, Furkan
dc.contributor.authorÇetin, Mustafa
dc.contributor.authorTanboğa, İbrahim Halil
dc.date.accessioned2023-10-30T06:30:46Z
dc.date.available2023-10-30T06:30:46Z
dc.date.issued2023en_US
dc.identifier.citationAkyuz, S., Calik, A. N., Yaylak, B., Onuk, T., Eren, S., Kolak, Z., Mollaalioglu, F., Durak, F., Cetin, M., & Tanboga, I. H. (2023). Comparison of Ticagrelor and Clopidogrel in Patients with Acute Coronary Syndrome at High Bleeding or Ischemic Risk. The American journal of cardiology, S0002-9149(23)01198-0. Advance online publication. https://doi.org/10.1016/j.amjcard.2023.10.046en_US
dc.identifier.issn0002-9149
dc.identifier.issn1879-1913
dc.identifier.issn0002-9149
dc.identifier.urihttps://doi.org/10.1016/j.amjcard.2023.10.046
dc.identifier.urihttps://hdl.handle.net/11436/8597
dc.description.abstractCurrent guidelines recommend individualizing the choice and duration of P2Y12 inhibitor therapy based on the trade-off between bleeding and ischemic risk. However, whether a potent P2Y12 inhibitor (ticagrelor) or a less potent one (clopidogrel) is more appropriate in patients with acute coronary syndrome (ACS) in the setting of high bleeding or ischemic risk is not clear. The aim of this study is to compare the clinical outcomes of clopidogrel and ticagrelor in patients with ACS at high bleeding or ischemic risk. A total of 5713 patients with ACS were included in this retrospective study. The Cox proportional hazard regression model were adjusted applying the inverse probability weighted (IPW) approach to reduce treatment selection bias. The primary clinical outcome was all-cause death. Secondary outcomes included in-hospital death, ACS, target vessel revascularization, stent thrombosis, stroke, or clinically significant or major bleeding. The median follow-up duration was 53.6 months. After multivariable Cox model using IPW, all-cause death in the overall population and subgroups of patients at high bleeding risk, and/or at high ischemic risk were not significantly different between clopidogrel and ticagrelor. Rates for secondary outcomes were also similar between the groups. In conclusion, ticagrelor and clopidogrel are associated with comparable clinical outcomes among patients with ACS irrespective of bleeding and ischemic risk.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectACSen_US
dc.subjectAcute coronary syndromeen_US
dc.subjectDAPTen_US
dc.subjectDual antiplatelet therapyen_US
dc.subjectHBRen_US
dc.subjectHigh bleeding risken_US
dc.subjectHIRen_US
dc.subjectHigh ischemic risken_US
dc.subjectIPWen_US
dc.subjectInverse probability weighteden_US
dc.titleComparison of ticagrelor and clopidogrel in patients with acute coronary syndrome at high bleeding or ischemic risken_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorÇetin, Mustafa
dc.identifier.doi10.1016/j.amjcard.2023.10.046en_US
dc.identifier.volume9149en_US
dc.identifier.issue23en_US
dc.identifier.startpage01198-0en_US
dc.relation.journalThe American Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record